Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies

Abstract The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~ 300 amino acid receptor binding domain...

Full description

Saved in:
Bibliographic Details
Main Authors: Asheley P. Chapman, Xiaoling Tang, Joo R. Lee, Asiya Chida, Kristina Mercer, Rebekah E. Wharton, Markus Kainulainen, Jennifer L. Harcourt, Roosecelis B. Martines, Michelle Schroeder, Liangjun Zhao, Anton Bryksin, Bin Zhou, Eric Bergeron, Brigid C. Bollweg, Azaibi Tamin, Natalie Thornburg, David E. Wentworth, David Petway, Dennis A. Bagarozzi, M. G. Finn, Jason M. Goldstein
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/62c76690f37c478981f0b0dd9033fece
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/62c76690f37c478981f0b0dd9033fece

Similar Items